Updated: Eisai says Alzheimer’s drug keeps working after three years. But weaknesses in study raise questions

PHILADELPHIA — Ever since Eisai first revealed data from its pivotal Alzheimer’s disease study two years ago, the company has argued that treating patients with Leqembi …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Breast cancer is deadlier for Black women. A study of mammograms could help close the gap

Are 3D mammograms better than standard 2D imaging for catching advanced cancers? A clinical trial is recruiting thousands of volunteers — including a large number of Black

October 17, 2023

Handheld Device Detects Alzheimer’s Biomarkers; Long COVID Smell Loss; MS Fatigue

A handheld wireless device using a graphene field-effect transistor sensor detected Alzheimer’s and Parkinson’s biomarkers amyloid beta, tau, and alpha-synuclein. (Proceedings of the National Academy

November 15, 2023

Gabapentinoids in COPD Patients May Raise Risk for Severe Exacerbations

Gabapentinoid use in patients with chronic obstructive pulmonary disease (COPD) was associated with a higher risk for severe exacerbations, a population-based cohort study from Canada

January 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.